However, a recent study by Cloughesy et al. demonstrated that recurrent glioblastoma patients receiving neoadjuvant treatment with pembrolizumab (anti-PD-1), followed by adjuvant therapy after surgery, had significantly improved OS compared to those receiving only adjuvant post-surgical pembrolizumab treatment [12,19]. The gene discussed is PDCD1; the disease is glioblastoma.